Triplet systemic therapy for hormone-sensitive prostate cancer : a critical review with a multidisciplinary approach
Zapatero, Almudena (Hospital Universitario de la Princesa (Madrid))
Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Espanya, Madrid))
Rodríguez Antolín, Alfredo (Hospital Universitario 12 de Octubre (Madrid))
Couñago, Felipe (Universidad Europea de Madrid)
Borque-Fernando, Ángel (Hospital Universitario Miguel Servet (Saragossa))
Maroto Rey, Pablo (Institut de Recerca Sant Pau)
Sanmamed, Noelia (Hospital Clínico San Carlos (Madrid))
Domínguez Esteban, Mario (Hospital Universitario Marqués de Valdecilla (IDIVAL))
López Valcárcel, Marta (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Manneh, Ray (Society of Oncology and Hematology of Cesar)
Sala-González, Núria (Hospital Universitari de Girona Doctor Josep Trueta)
Universitat Autònoma de Barcelona. Departament de Medicina

Data:	2025
Resum:	This article aims to critically evaluate the evidence for triplet therapy consisting of androgen deprivation therapy (ADT), docetaxel and a second-generation androgen receptor pathway inhibitor ([ARPI]; abiraterone, enzalutamide, darolutamide or apalutamide) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), and what this evidence reveals regarding the use of these treatments in clinical practice. A search of PubMed, Medline, Embase, Cochrane, Scopus and Web of Science was conducted in April 2024 to identify relevant prospective and retrospective observational trials, randomized controlled trials (RCTs) and meta-analyses. The search identified 52 relevant articles: six full articles and 31 abstracts based on three RCTs, one observational study and 14 meta-analyses. Abiraterone- or darolutamide-containing triplet therapy was significantly better than ADT + docetaxel for improving overall survival in all study populations, particularly subgroups with high-volume and/or synchronous disease. The tolerability of ADT + docetaxel and triplet therapy were similar with most adverse events related to docetaxel. There were no data comparing triplet therapy with ADT + ARPI doublet therapy. Triplet therapy appears to be the most effective first-line regimen for men with mHSPC, good performance status and high-volume and synchronous metastases. Darolutamide-based triplet therapy may also be of benefit in other patients with high- or low-risk disease. Careful consideration of the risks and benefits are required to determine which patients can be spared from receiving docetaxel and rather be treated with alternative regimens.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Matèria:	Androgen deprivation therapy ; Androgen receptor-targeted therapy ; Docetaxel ; Hormone-sensitive prostate cancer ; Metastatic prostate cancer
Publicat a:	Oncology Reviews, Vol. 19 (2025) , art. 1599292, ISSN 1970-5565

DOI: 10.3389/or.2025.1599292
PMID: 40787089

13 p, 1.2 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats